BTIG reiterates Neogenomics stock Buy rating on strong test growth
BTIG reiterated a Buy rating and $28.00 target on Neogenomics (NEO) after Q3 results. Shares trade at $17.99, up 75% YoY. Revenue grew 11% YoY, with next-gen sequencing revenue up 29%. Management raised guidance and plans to expand sales force. NEO reported Q3 earnings of $0.07 per share, beating estimates.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift sentiment, supporting a bullish short‑term outlook.
Market read
Earnings beat and upgraded target provide a clear catalyst for NEO, making it a candidate for short‑term buying.
What to watch
Potential headwinds from reimbursement pressures and competition in NGS testing.
Background
NeoGenomics reported Q3 2026 revenue of $209 million and adjusted EPS of $0.07, beating estimates. BTIG raised its target to $28, implying ~56% upside from the current $17.99 price.
Ticker impact
BTIG reiterated a Buy rating with a $28 price target after NeoGenomics reported Q3 earnings that beat revenue estimates and raised guidance.
likely upward pressure as the market prices in the raised guidance and target.
The earnings beat and guidance raise expectations for future revenue growth, prompting buying interest.
Market effects
Positive earnings may lift other precision‑oncology and sequencing companies.
U.S. biotech sector could see modest gains.
Limited to healthcare investors; no broad market effect.
Counterpoint
The stock may already be overbought after a 75% YTD rally; price could stall.
Key entities
- companyNeoGenomics Inc.
U.S. precision‑oncology sequencing firm.
- analystBTIG
Equity research firm that issued the buy rating.
